Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2017

01-12-2017 | Pancreatic Tumors

Comment on: MicroRNA Expression as a Predictive Marker for Gemcitabine Response After Surgical Resection of Pancreatic Cancer

Authors: Sameer A. Dhayat, MD, Wolf Arif Mardin, MD, Norbert Senninger, MD, FACS

Published in: Annals of Surgical Oncology | Special Issue 3/2017

Login to get access

Excerpt

We read with great interest the study by Ohuchida et al. investigating microRNAs (miRNAs) as prognostic biomarkers for chemoresistance in pancreatic ductal adenocarcinoma (PDAC).1 We congratulate the authors for advancing the research on molecular markers predicting chemotherapy response in this aggressive carcinoma entity. Their translational study evaluates in vitro results in a clinical setting and is an important contribution towards understanding and overcoming chemoresistance in PDAC patients. Deregulated miRNAs were retrospectively investigated in patients who underwent resection for PDAC. Expression profiling identified several miRNAs aberrantly expressed in two human PDAC cell lines and clinical tissue samples that were significantly correlated with clinical outcome, most notably miRNA-142-5p, which was an independent prognostic marker for longer survival in patients treated with gemcitabine. …
Literature
1.
Ohuchida K, Mizumoto K, Kayashima T, et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18(8):2381–87.CrossRefPubMedPubMedCentral
2.
Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70(11):4528–38.CrossRefPubMed
Metadata
Title
Comment on: MicroRNA Expression as a Predictive Marker for Gemcitabine Response After Surgical Resection of Pancreatic Cancer
Authors
Sameer A. Dhayat, MD
Wolf Arif Mardin, MD
Norbert Senninger, MD, FACS
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6207-6

Other articles of this Special Issue 3/2017

Annals of Surgical Oncology 3/2017 Go to the issue

Colorectal Cancer

Vitamin D Status May Explain Some of the Racial Disparities in Rectal Cancer

Erratum

Erratum to: Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study

Head and Neck Oncology

Partial Verification Distorts Estimates of Sensitivity in Diagnostic Accuracy Studies for Fine-Needle Aspiration Cytology

Breast Oncology

Primary Locoregional Treatment in Metastatic Breast Cancer: A Reply

Erratum

Erratum to: E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer

Pancreatic Tumors

Reply to “Analysis of 340 Patients with Solid Pseudopapillary Tumors of the Pancreas: A Closer Look at Patients with Metastatic Disease; Methodologic Issues,” by Safiri, Saeid et al.